Name: Tovecimig (CTX-009) in Second-line advanced biliary tract cancer: Generic, brand name and therapeutic class of product
Published: 2026-09-21T22:15:09-04:00

Manufacturer: Compass Therapeutics

“Tovecimig (CTX-009), our bispecific antibody targeting DLL4 and VEGF-A, is currently being evaluated in a randomized Phase 2/3 trial in the United States in combination with paclitaxel in patients with biliary tract cancer (“BTC”) who received one prior treatment regimen.” (opens the source at this quote in a new tab)
“We have licensed exclusive global rights to tovecimig, outside of South Korea, from ABL Bio, Inc. (“ABL Bio”), a South Korea-based clinical-stage company focused on developing antibody therapeutics. South Korean rights are held by Handok Pharmaceuticals, Inc. (“Handok”) and China rights were out-licensed to Elpiscience Biopharmaceuticals Co., Limited (“Elpiscience”).” (opens the source at this quote in a new tab)

Field	Quoted record
Lead sponsor	“Compass Therapeutics”

Nonproprietary name and development codes

“our Phase 2/3 combination study of tovecimig, which is our new nonproprietary name for CTX-009, in patients with advanced BTC” (opens the source at this quote in a new tab)

“A bispecific antibody targeting VEGF and DLL4 (ABL001/NOV1501/TR009) demonstrates more potent in vitro and in vivo biological activity compared to VEGF or DLL4 targeting monoclonal antibodies alone” (opens the source at this quote in a new tab)

“ABL Bio announced Wednesday that Tovecimig (CTX-009/ABL001), an innovative bispecific antibody cancer treatment, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA).” (opens the source at this quote in a new tab)

Brand name

No evidence found.

Therapeutic class

“Our lead product candidate, tovecimig (formerly known as CTX-009), is a bispecific antibody targeting Delta-like ligand 4 (“DLL4”), a ligand of Notch-1, and vascular endothelial growth factor A (“VEGF-A”).” (opens the source at this quote in a new tab)

“CTX-009 is a recombinant bispecific antibody that contains two single chain variable fragments (scFv) binding to human DLL4 linked to the C-terminus of heavy chains that bind to human VEGF-A” (opens the source at this quote in a new tab)

Originator: ABL Bio

“Our wholly owned subsidiary Trigr Therapeutics, Inc. (“TRIGR”) and ABL Bio, a South Korean biotechnology company, entered into an exclusive global (excluding South Korea) license agreement (the “TRIGR License Agreement”) which granted TRIGR a license to ABL001 (renamed CTX-009 and subsequently tovecimig). Under the terms of the agreement, ABL Bio and TRIGR would jointly develop tovecimig, with ABL Bio responsible for development of tovecimig throughout the end of Phase 1 clinical trials and TRIGR responsible for the development of tovecimig from Phase 2 and onward.” (opens the source at this quote in a new tab)

“Tovecimig is a bispecific antibody developed by ABL Bio and licensed to Compass Therapeutics.” (opens the source at this quote in a new tab)

Manufacturing

“We do not currently own or operate manufacturing facilities for the production of clinical quantities of our product candidates. We have relied on, and intend to continue to rely on, qualified third-party contract manufacturers to produce our product candidates, including clinical supplies to support our clinical trials.” (opens the source at this quote in a new tab)